Reference

Direct or indirect action of histamine on dopamine metabolism in the rat striatum?

Direct or indirect action of histamine on dopamine metabolism in the rat striatum?. Nowak, Jerzy Z.; Pilc, Andrzej (Inst. Pharmacol., Pol. Acad. Sci., Lodz, Pol.). Eur. J. Pharmacol., 46(2), 171-5 (English) 1977. CODEN: EJPHAZ. DOCUMENT TYPE: Journal CA Section: 2 (Hormone Pharmacology) Intraventricular administration of 500 mg of 2-pyridylethylamine [65330-33-8], an agonist of the histamine (I) [51-45-6] H1-receptor, produced a 20% increase of striatal homovanillic acid (II) [306-08-1] in the rat whereas the I H2-receptor agonist 4-methylhistamine [36507-31-0] had no influence on II and 3,4-dihydroxyphenylacetic acid (III) [102-32-9] levels. L-Histidine-HCl [1007-42-7] (1.5 g/kg) or amodiaquine-HCl [69-44-3] (60 mg/kg) given i.p. increased II and III levels to the same extent as did pyridylethylamine. Histidine combined with tremorine had an additive effect with respect to the increase of dopamine acidic metabolites whereas mepyramine slightly attenuated the tremorine-induced rise of II.

Therapeutic agent for inflammatory bowel disease and TNF-a production inhibitor containing specified amino acids

All Rights Reserved. Therapeutic agent for inflammatory bowel disease and TNF-a production inhibitor containing specified amino acids. Matsumoto, Hideki; Okutsu, Tomohisa; Takeda, Tomoko; Suzuki, Hideki; Yano, Tetsuo; Hashimoto, Masaki; Ono, Miho; Suzuki, Manabu (Ajinomoto Co., Inc., Japan). PCT Int. Appl. WO 2007004613 A1 11 Jan 2007, 20pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-JP313236 3 Jul 2006. PRIORITY: JP 2005-193591 1 Jul 2005. DOCUMENT TYPE: Patent CA Section: 18 (Animal Nutrition) Section cross-reference(s): 1, 63 Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the prodn. of TNF-a. The therapeutic or prophylactic agent for inflammatory bowel disease comprises at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day. The TNF-a prodn.In this experiment, several chemicals are used like 1007-42-7 and 56-87-1 inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day. .